| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Blue Mesa Health | Digital Diabetes Prevention Program | Transform for Prediabetes | Transformemos for Prediabetes
First Care Medical Services is a Fosston, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Medical Practice Innovations is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Awaken Foundation / Awaken hEalth Institute is a Three Rivers, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.